NCT04878484
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: HLA+, ESO
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patients must have tumors that are HLA-A*0201 positive & NY-ESO-1 positive
Exclusions: Patients with untreated or symptomatic brain metastasis
https://ClinicalTrials.gov/show/NCT04878484